Impact of AI-assisted Medication Dosing on Adherence, Cognition, and Treatment Perception in Elderly Patients

Authors

  • Abiha Zainab M.Phil. Scholar, Saulat Institute of Pharmaceutical Sciences, Quaid-i-Azam University, Islamabad, Pakistan.
  • Qurat-ul-Ain Zia BS Graduate, Saulat Institute of Pharmaceutical Sciences, Quaid-I-Azam University, Islamabad, Pakistan.
  • Walija Maryum BS Graduate, Saulat Institute of Pharmaceutical Sciences, Quaid-I-Azam University, Islamabad, Pakistan.
  • Hunaina Nadeem BS Graduate, Saulat Institute of Pharmaceutical Sciences, Quaid-I-Azam University, Islamabad, Pakistan.
  • Fiza Iman M.Phil. Scholar, National Institute of Psychology, Quaid-I-Azam University, Islamabad, Pakistan.

DOI:

https://doi.org/10.55737/trt/v-i.226

Keywords:

Medication Adherence, Cognitive Performance, Medication Management, AI-Assisted Medication, Elderly Patients

Abstract

The focus of this study is to evaluate the effectiveness of an AI-assisted medication dosing system in improving medication compliance, cognitive function related to medication management, and treatment perception among elderly patients. 80 elderly patients undergo a quantitative, quasi-experimental pretest–posttest design, who received AI-guided dosing recommendations with clinician oversight for 12 weeks. Morisky Medication Adherence Scale (MMAS-8) is used to assess medication adherence, cognitive performance using the Mini-Mental State Examination (MMSE), and Structured Technology Acceptance Questionnaire is used for treatment perception. Pre- and post-intervention scores were compared by using paired sample t-tests and Pearson’s correlation analysis inspects relationships among study variables. The results showed a substantial increase in compliance and therapeutic adherence (pre-intervention mean = 5.42 ± 1.21; post-intervention mean = 7.13 ± 0.96; t = 8.74, p < 0.001), cognitive function (pre-intervention mean = 24.18 ± 2.64; post-intervention mean = 26.03 ± 2.31; t = 6.11, p < 0.001), and treatment evaluation (pre-intervention mean = 3.01 ± 0.54; post-intervention mean = 4.21 ± 0.47; t = 10.38, p < 0.001). Important positive interrelations were observed between adherence and cognitive performance (r = 0.58, p < 0.001), adherence and treatment perspective (r = 0.66, p < 0.001), and cognitive function and treatment performances (r = 0.49, p < 0.001). The conclusion illustrated that AI-assisted medication dosing significantly enhances adherence, cognitive ability for medication management, and patient acceptance, supporting its amalgamation into geriatric pharmacotherapy to enhance its clinical efficacy

Author Biography

  • Abiha Zainab, M.Phil. Scholar, Saulat Institute of Pharmaceutical Sciences, Quaid-i-Azam University, Islamabad, Pakistan.

    Corresponding Author: [email protected]

References

Campbell, N. L., Boustani, M. A., Skopelja, E. N., Gao, S., Unverzagt, F. W., Murray, M. D., & Callahan, C. M. (2012). Medication adherence in older adults with cognitive impairment: A systematic evidence-based review. The American Journal of Geriatric Pharmacotherapy, 10(3), 165–177. https://doi.org/10.1016/j.amjopharm.2012.04.004

Davis, F. D. (1989). Perceived usefulness, perceived ease of use, and user acceptance of information technology. MIS Quarterly, 13(3), 319–340. https://doi.org/10.2307/249008

DiMatteo, M. R., Lepper, H. S., & Croghan, T. W. (2000). Depression is a risk factor for noncompliance with medical treatment. Archives of Internal Medicine, 160(14), 2101–2107. https://doi.org/10.1001/archinte.160.14.2101

Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12(3), 189–198. https://doi.org/10.1016/0022-3956(75)90026-6

Gnjidic, D., Hilmer, S. N., Blyth, F. M., Naganathan, V., Waite, L., Seibel, M. J., Handelsman, D. J., Cumming, R. G., & Le Couteur, D. G. (2012). Polypharmacy cutoff and outcomes: Five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. Journal of Clinical Epidemiology, 65(9), 989–995. https://doi.org/10.1016/j.jclinepi.2012.02.018

Herrera, A. P., Snipes, S. A., King, D. W., Torres-Vigil, I., Goldberg, D. S., & Weinberg, A. D. (2010). Disparate inclusion of older adults in clinical trials: Priorities and opportunities for policy and practice change. American Journal of Public Health, 100(Suppl 1), S105–S112. https://doi.org/10.2105/AJPH.2009.162982

Insel, K. C., Morrow, D. G., Brewer, B. B., & Figueredo, A. J. (2006). Executive function, working memory, and medication adherence among older adults. The Journals of Gerontology Series B: Psychological Sciences and Social Sciences, 61(2), P102–P107. https://doi.org/10.1093/geronb/61.2.P102

Khezrian, M., McNeil, C. J., Murray, A. D., & Myint, P. K. (2020). An overview of prevalence, determinants and health outcomes of polypharmacy. Therapeutic Advances in Drug Safety, 11, 1–10. https://doi.org/10.1177/2042098620933741

Maher, R. L., Hanlon, J., & Hajjar, E. R. (2014). Clinical consequences of polypharmacy in elderly. Expert Opinion on Drug Safety, 13(1), 57–65. https://doi.org/10.1517/14740338.2013.827660

Mangoni, A. A., & Jackson, S. H. D. (2004). Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications. British Journal of Clinical Pharmacology, 57(1), 6–14. https://doi.org/10.1046/j.1365-2125.2003.02007.x

Morisky, D. E., Ang, A., Krousel-Wood, M., & Ward, H. J. (2008). Predictive validity of a medication adherence measure for hypertension control. Journal of Clinical Hypertension, 10(5), 348–354. https://doi.org/10.1111/j.1751-7176.2008.07572.x

Nieuwlaat, R., Wilczynski, N., Navarro, T., Hobson, N., Jeffery, R., Keepanasseril, A., … Haynes, R. B. (2014). Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews, (11), CD000011. https://doi.org/10.1002/14651858.CD000011

Osterberg, L., & Blaschke, T. (2005). Adherence to medication. The New England Journal of Medicine, 353(5), 487–497. https://doi.org/10.1056/NEJMra050100

Sabaté, E. (Ed.). (2003). Adherence to long-term therapies: evidence for action. World health organization.

Serrano, D. R., Luciano, F. C., Anaya, B. J., Ongoren, B., Kara, A., Molina, G., Ramirez, B. I., Sánchez-Guirales, S. A., Simon, J. A., Tomietto, G., Rapti, C., Ruiz, H. K., Rawat, S., Kumar, D., & Lalatsa, A. (2024). Artificial intelligence (AI) applications in drug discovery and drug delivery: Revolutionizing personalized medicine. Pharmaceutics, 16(10), 1328. https://doi.org/10.3390/pharmaceutics16101328

Sutton, R. T., Pincock, D., Baumgart, D. C., Sadowski, D. C., Fedorak, R. N., & Kroeker, K. I. (2020). An overview of clinical decision support systems: Benefits, risks, and strategies for success. Journal of Biomedical Informatics, 109, 103466. https://doi.org/10.1016/j.jbi.2020.103466

Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. Nature Medicine, 25(1), 44–56. https://doi.org/10.1038/s41591-018-0300-7

World Health Organization. (2003). Adherence to long-term therapies: Evidence for action. WHO.

World Health Organization. (2018). Ageing and health. WHO. https://www.who.int/news-room/fact-sheets/detail/ageing-and-health

Downloads

Published

2026-03-30

Issue

Vol. 5 No. 1 (2026): Issue 1

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

Zainab, A., Zia, Q.- ul-A., Maryum, W., Nadeem, H., & Iman, F. (2026). Impact of AI-assisted Medication Dosing on Adherence, Cognition, and Treatment Perception in Elderly Patients. The Regional Tribune, 5(1), 300-309. https://doi.org/10.55737/trt/v-i.226